The latest price target for Anebulo Pharmaceuticals (NASDAQ:ANEB) was reported by Benchmark on November 19, 2024. The analyst firm set a price target for $8.00 expecting ANEB to rise to within 12 months (a possible 384.85% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ:ANEB) was provided by Benchmark, and Anebulo Pharmaceuticals reiterated their speculative buy rating.

There is no last upgrade for Anebulo Pharmaceuticals

There is no last downgrade for Anebulo Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on November 19, 2024 so you should expect the next rating to be made available sometime around November 19, 2025.

While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a reiterated with a price target of $8.00 to $8.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $1.65, which is out of the analyst’s predicted range.